Loading...
Keywords
Last Name
Institution

Rachel L. Chevalier, MD

TitleDirector of CMH Fellow's Grant Writing Curriculum, Department of Peds/GME
InstitutionChildren's Mercy Kansas City
DepartmentGastroenterology
Address2401 Gillham Rd
Kansas City MO 64108
ORCID ORCID Icon0000-0001-7628-6007 Additional info
vCardDownload vCard
    Other Positions
    TitleMedical Director of Eosinophilic Gastrointestinal Diseases Program, DOP/Gastroenterology, Hepatology and Nutrition
    InstitutionChildren's Mercy Kansas City
    DepartmentGastroenterology

    TitleResearch Assistant Professor
    InstitutionUniversity of Kansas Medical Center
    DepartmentPediatrics

    TitleAssociate Professor
    InstitutionUniversity of Missouri-Kansas City
    DepartmentPediatrics


    Collapse Biography 
    Collapse education and training
    Massachusetts Institute of Technology, Cambridge, MASB2007Chemical-Biological Engineering
    West Virginia University School of Medicine, Morgantown, WVMD2011Doctorate of Medicine
    Mayo Clinic College of Medicine, Rochester, MNResidency2014Pediatrics
    University of California San Francisco, San Francisco, CAFellowship2017Pediatric Gastroenterology
    Collapse awards and honors
    2020George Ferry Young Investigator Award, NASPGHAN

    Collapse Overview 

    Collapse Research 
    Collapse research overview
    I am an early-career physician scientist and board certified pediatric gastroenterologist. Due to my clinical experiences, I developed an interest in finding better ways to treat the atopic inflammatory condition Eosinophilic Esophagitis (EoE). To improve drug delivery, my lab is interested in identifying mechanisms by which drugs currently fail. We investigate
    the pharmacogenetics of budesonide--one of the most common EoE treatments prescribed. We are
    engineering new drug delivery platforms to maximize medication targeting to the esophagus. Our
    research intention is to quickly benefit patients, families, and providers in making educated decisions on treatment while guiding future drug delivery research. My research has provided many skills including genotyping, biological assays, microfabrication, use of polymers, picoliter volume printing, and experimental design. I am bridging my interests in engineering and medicine into translational work designed to improve drug delivery for children suffering from gastrointestinal diseases.

    Collapse Bibliography 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Shubow S, Gunsior M, Rosenberg A, Wang YM, Altepeter T, Guinn D, Rajabiabhari M, Kotarek J, Mould DR, Zhou H, Cheifetz AS, Garces S, Chevalier R, Gavan S, Trusheim MR, Rispens T, Bray K, Partridge MA. Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities - a Workshop Report. AAPS J. 2025 Mar 14; 27(2):62. PMID: 40087239.
      View in: PubMed
    2. Kumar A, Tatarian J, Shakhnovich V, Chevalier RL, Sudman M, Lovell DJ, Thompson SD, Becker ML, Funk RS. Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis. Metabolites. 2024 Sep 16; 14(9). PMID: 39330506.
      View in: PubMed
    3. Keever-Keigher MR, Harvey L, Williams V, Vyhlidal CA, Ahmed AA, Johnston JJ, Louiselle DA, Grundberg E, Pastinen T, Friesen CA, Chevalier R, Smail C, Shakhnovich V. Genomic insights into pediatric intestinal inflammatory and eosinophilic disorders using single-cell RNA-sequencing. Front Immunol. 2024; 15:1420208. PMID: 39192974.
      View in: PubMed
    4. Sandritter T, Chevalier R, Abt R, Shakhnovich V. Pharmacogenetic Testing for the Pediatric Gastroenterologist: Actionable Drug-Gene Pairs to Know. Pharmaceuticals (Basel). 2023 Jun 16; 16(6). PMID: 37375836.
      View in: PubMed
    5. Pandya A, Adah E, Jones B, Chevalier R. The evolving landscape of immunotherapy for the treatment of allergic conditions. Clin Transl Sci. 2023 08; 16(8):1294-1308. PMID: 37170653.
      View in: PubMed
    6. Kaur P, Chevalier R, Friesen C, Ryan J, Sherman A, Page S. Diagnostic role of fractional exhaled nitric oxide in pediatric eosinophilic esophagitis, relationship with gastric and duodenal eosinophils. World J Gastrointest Endosc. 2023 May 16; 15(5):407-419. PMID: 37274554.
      View in: PubMed
    7. Chevalier R, Attard T, Van Driest SL, Shakhnovich V. A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens. Expert Opin Drug Metab Toxicol. 2023 02; 19(2):53-56. PMID: 36919492.
      View in: PubMed
    8. Chevalier R. siRNA Targeting and Treatment of Gastrointestinal Diseases. Clin Transl Sci. 2019 11; 12(6):573-585. PMID: 31309709.
      View in: PubMed
    9. Haas L, Chevalier R, Major BT, Enders F, Kumar S, Tung J. Biologic Agents Are Associated with Excessive Weight Gain in Children with Inflammatory Bowel Disease. Dig Dis Sci. 2017 11; 62(11):3110-3116. PMID: 28895012.
      View in: PubMed
    Collapse presentations
    1. Chevalier, R Oral Presentation and Panel (Invited) “Inflammatory Bowel Disease in Sports Medicine” American Medical Society for Sports Medicine (AMSSM) Annual Meeting Kansas City, MO (April 2025)

    2. Chevalier, R GI Grand Rounds (Invited) “Pharmacogenetics in Eosinophilic Esophagitis: Drug metabolism to guide EoE management” Yale University Pediatric GI Division Virtual (February 2025)

    3. Chevalier, R Oral Presentation (Invited) “How to Choose A Successful Research Project” North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition First Year Fellows Conference (invited) Orlando, FL (January 2025)

    4. Chevalier, R Oral Platform Presentation, “Targeting to Treat: Drug metabolism to guide EoE management” North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Annual Meeting Orlando, FL (November 2024)

    5. Chevalier, R Oral Platform Presentation, “Swallowed Topical Steroids and Proton Pump Inhibitors for EoE” North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Single Topic Symposium Orlando, FL (November 2024)

    6. Chevalier, R Platform Presentation and Panel “Therapeutic Drug Monitoring for the Well Being of Children” Federal Drug Administration/ Center for Drug Evaluation and Research Workshop on Therapeutic Drug Monitoring in Inflammatory Bowel Disease Washington, DC (February 2024)

    7. Chevalier, R., Oral Platform Presentation, “Cyp3A5 Contribution to Budesonide Treatment Failure in Children with Eosinophilic Esophagitis”, Digestive Disease Week, AASLD/AGA/ASGE/SSAT.Virtual (May 2021).

    8. Chevalier, R., Oral Presentation, “Cyp3A5 Contribution to Budesonide Treatment Failure in Children with Eosinophilic Esophagitis”, American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, American Society of Clinical Pharmacology and Therapeutics. Virtual (March 2021).

    1. Lee J, Hajjat T (Hosts) Chevalier, R (Guest) “Update on Topical Steroids for Eosinophilic Esophagitis” Bowel Sounds 27 Jan 2025
    Chevalier's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (53) concept(s)
    _
    Co-Authors Expand Description
    See all (8) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department